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Studies of immune system metabolism (‘‘immunometabolism’’) segregate along two paths. The first investi-
gates the effects of immune cells on organs that regulate whole-body metabolism, such as adipose tissue
and liver. The second explores the role of metabolic pathways within immune cells and how this regulates
immune response outcome. Distinct metabolic pathways diverge and converge at many levels, and, there-
fore, cells face choices as to how to achieve their metabolic goals. There is interest in fully understanding
how and why immune cells commit to particular metabolic fates and in elucidating the immunologic conse-
quences of reaching a metabolic endpoint by one pathway versus another. This is particularly intriguing,
given that metabolic commitment is influenced not only by substrate availability but also by signaling path-
ways elicited by metabolites. Thus, metabolic choices in cells enforce fate and function, and this area will be
the subject of this review.The immune system encompasses a heterogeneous population
of cells that, for the most part, are relatively quiescent in the
steady state but share the ability to rapidly respond to infection,
inflammation, and other perturbations. Responses are regulated
by a broad range of cell-type-specific and/or shared activating
and inhibitory receptors that are responsive to pathogen-derived
or immune-system-intrinsic signals. The response that is
mounted by immune cells typically involves changes in the
expression of large numbers of genes and results in the acquisi-
tion of new functions, such as the high output production of
cytokines, lipid mediators, tissue remodeling enzymes, toxic
gases, and the ability to migrate through tissues and/or undergo
cellular division. There is a growing appreciation of the fact that
transitions between quiescent and activated states require the
apportioning of nutrients into different pathways, and, therefore,
there is a strong interest in how metabolic pathways are regu-
lated to support or direct functional changes.
The need to produce ATP to provide energy for cellular func-
tion is, of course, essential in both quiescent and activated cells.
Glucose can be used to fuel this process through two integrated
pathways. The first of these, glycolysis, involves the conversion
of glucose to pyruvate in the cytoplasm. In this pathway, phos-
phates are transferred from glycolytic intermediates to ADP for
the generation of ATP. The second pathway, the tricarboxylic
acid (TCA) cycle, generates the reducing equivalents nicotin-
amide adenine dinucleotide (NADH) and flavin adenine dinucle-
otide (FADH2), which donate electrons to the electron transport
chain to fuel oxidative phosphorylation (OXPHOS), the process
by which ATP is generated in the mitochondria. Glycolysis and
the TCA cycle can be integrated when pyruvate is converted
into acetyl-CoA, which enters the TCA cycle. To differing de-
grees, cells also have the flexibility to metabolize other sub-
strates, such as glutamine via glutaminolysis or fatty acids via
b-oxidation, to replenish the TCA cycle and fuel OXPHOS. Under
hypoxic conditions, cells can produce ATP solely by the break-
down of glucose via glycolysis, pyruvate being diverted primarily
toward lactate rather than acetyl-CoA. In some cases, cells pref-erentially use glycolysis for ATP generation, even when oxygen
isn’t limiting—a process known as aerobic glycolysis or Warburg
metabolism. Thus, as might be expected, cells have several op-
tions for producing ATP, and activity between different metabolic
pathways will be influenced, to a great extent, by the relative
availability of glucose, glutamine, and fatty acids and whether
there is sufficient oxygen to utilize OXPHOS. As has been
pointed out before, in sufficiently fed metazoan organisms in
the steady state, nutrient availability is regulated centrally, and
the ability of any given cell type to access nutrients will depend
on their ability to express appropriate transporters and enzymes
within the metabolic pathways that permit the utilization of that
nutrient (Thompson, 2011). Therefore, the regulated expression
and posttranscriptional control of pathway-specific genes and/
or proteins assume key roles in dictating the metabolic profile
of a cell under specific circumstances. In the immune system,
this level of regulation is imposed by growth factor cytokines
and by key activating receptors, such as toll-like receptors
(TLRs) on myeloid cells and costimulatory receptors on T cells.
Interconnections betweenmetabolic pathways are notoriously
complex, and, therefore, superficially simple choices between
aerobic glycolysis, or the oxidation of various substrates in the
mitochondria for ATP production, will have enormous ramifica-
tions on the outcomes of key ancillary metabolic processes,
such as the pentose phosphate pathway (PPP, an offshoot of
glycolysis that generates reducing equivalents in the form of
nicotinamide adenine dinucleotide phosphate [NADPH] and,
ultimately, is important for the synthesis of pentose sugars),
the synthesis of fatty acids, and the production of lipid ligands
for nuclear hormone receptors. Thus, regulated changes in
metabolism are key to function. The focus of this article is not
on areas that have been thoroughly addressed in recently pub-
lished reviews, but, rather, this article is centered around
growing interest in determining the extent to which, during
changes in immune cell function, metabolic changes are instruc-
tive versus responsive. Further, the emphasis on T cells, macro-
phages, and dendritic cells reflects not only our researchImmunity 38, April 18, 2013 ª2013 Elsevier Inc. 633
Figure 1. Cell Fate and Function in the Immune System Is Supported by the Engagement of Metabolic Pathways
In this diagram, colored arrows represent pathways that have been shown to be used in the cell types indicated. Gray arrows indicate pathways that might be
used but have yet to be clearly defined, and dashed arrows indicate multiple steps shown in a single arrow.
(A) In activated neutrophils, M1 macrophages, and iNOS-expressing DCs stimulated with TLR agonists, Warburg metabolism dominates. ATP production and
cellular survival are dependent on glycolysis, themajority of pyruvate being converted to lactate. In this proglycolytic state, the PPP is active and provides NADPH
for key microbicidal pathways regulated by NADPH oxidase. Under these conditions, there is little evidence for OXPHOS, but maintenance of mitochondrial
potential and integrity are needed to maintain cell survival.
(B) Activated T cells engage OXPHOS and glycolysis. Most pyruvate is excreted as lactate, but some also enters the TCA cycle. Glutaminolysis is an important
pathway in these cells, given that glutamine replenishes TCA cycle intermediates as they are withdrawn for biosynthesis. Metabolizing glucose in the PPP can
yield both nucleotides and NADPH for lipid synthesis.
(C) Memory T cells, Treg cells, and alternatively activated macrophages use FAO for survival and to support function. Other pathways are depicted in gray
because the extent to which they are used in these cells, if at all, has not been established.
(D) Overview of the TCA cycle.
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nothing published, on other immune cell types.
Granulocytes
There is a general view that myeloid cells primarily use glycolysis
as a source of ATP (Kominsky et al., 2010). A fine example of this
axiom is provided by neutrophils—short-lived granulocytes
whose primary function is to rapidly enter sites of infection and
initiate microbial killing. Studies dating back to the 1950s have
shown that neutrophils are highly dependent on glucose for ATP
production via aerobic glycolysis (Figure 1A) (Sbarra and Karnov-
sky, 1959; Valentine and Beck, 1951). Consistent with this, neu-634 Immunity 38, April 18, 2013 ª2013 Elsevier Inc.trophils have few mitochondria and consume little oxygen (van
Raam et al., 2006). Upon activation by TLR agonists, or phagocy-
tosis of antibody-coated particles, neutrophils increase their con-
sumption of glucose and oxygen (Borregaard and Herlin, 1982).
However, this is not a reflection of increased oxidation of glucose
in the mitochondria, but, rather, it is a reflection of the Warburg
effect and increased activity through the PPP (Figure 1A), which
generates NADPH, an essential cofactor for the NADPH oxidase
that consumesoxygen for theproduction of the important neutro-
phil microbicidal product H2O2 (Dale et al., 2008).
The presence of nonfunctional mitochondria can be
dangerous because a loss of mitochondrial membrane potential
Immunity
Reviewcan lead to the release of cytochrome C into the cytoplasm and
the initiation of apoptosis (Galluzzi et al., 2012; van Raam et al.,
2006). However, despite the fact that they do not function to pro-
duce ATP, neutrophil mitochondria maintain their membrane po-
tential through the glycerol 3-phosphate shuttle, a pathway that
allows the receipt of electrons from glycolysis by complex III of
the electron transport chain (van Raam et al., 2008). In this
way, the mitochondria simultaneously contribute to redox bal-
ance and promote flux through the glycolytic pathway while
avoiding commitment to the apoptotic process. This extreme
commitment to Warburg metabolism may underlie the ability of
neutrophils to temporarily remain viable during netosis—the pro-
cess of releasing extracellular traps of mitochondrial DNA and
embedded microbicidal products (Remijsen et al., 2011). The
importance of glycolysis in the microbicidal functions of neutro-
phils is emphasized by the fact that netosis is NADPH-oxidase-
dependent (Kirchner et al., 2012).
Available evidence, albeit scant, indicates that eosinophils and
basophils are metabolically similar to neutrophils (Sher et al.,
1983; Sumbayev et al., 2009; Venge et al., 2003). A unifying
feature of granulocytes is that they are terminally differentiated
and largely incapable of proliferating in the periphery. It is inter-
esting to speculate that this aspect of their biology is directly
connected to their relative lack of mitochondrial function.
Dendritic Cells
Dendritic cells (DCs) are heterogeneous and can be categorized
into a large and growing number of subsets (Satpathy et al.,
2012). These cells are functionally united in standing at the
checkpoint between innate and adaptive immunity, given that
activated DCs participate in the initiation of inflammation and
play an essential role in the priming of T cell responses (Bancher-
eau et al., 2000). Activation can be driven via an array of recep-
tors for pathogen-associated molecular patterns and alarmins
that allow DCs to respond to infection or other changes in the
environment (Bianchi, 2007). As is the case for macrophages
(Geissmann et al., 2010), during inflammation, DCs can arise
from monocytes, and, consistent with this, there are metabolic
similarities in the way that monocyte-derived dendritic cells
and macrophages respond to certain stimuli. Aspects of this
area have been reviewed recently elsewhere (O’Neill and Hardie,
2013).
Many studies on DC biology have utilized cells derived from
bone marrow by culture in granulocyte macrophage colony-
stimulating factor as a model for monocyte-derived and tumor
necrosis factor a (TNF-a)- and inducible nitric oxide synthase
(iNOS)-producing DCs. At rest, these cells oxidize glucose in
the mitochondria, engage OXPHOS, and consequently produce
relatively little lactate. However, after stimulation with TLR ago-
nists, they undergo a remarkable metabolic transformation in
which they become dependent on Warburg metabolism for sur-
vival (Krawczyk et al., 2010). Signaling through phosphatidyl
inositol 3-OH kinase (PI3K) and Akt is central to the regulation
of glycolytic metabolism (Locasale and Cantley, 2011; Shaw
and Cantley, 2006), and, consistent with this, PI3K and Akt
play an essential role in sustained commitment to glycolysis in
activated DCs (Krawczyk et al., 2010). In cells that have been
activated for >12 hr, despite the fact the glucose consumption
increases, glucose carbons no longer enter the TCA cycle, andmitochondrial oxygen consumption ceases (Everts et al., 2012;
Krawczyk et al., 2010). Rather, lactate production increases sub-
stantially, and cells survive by aerobic glycolysis alone
(Figure 1A). The reason for the collapse of mitochondrial respira-
tion in these cells is that activation leads to the expression of
iNOS, which produces the toxic gas NO from arginine at a high
rate (Everts et al., 2012). NO inhibits mitochondrial electron
transport by the nitrosylation of iron-sulfur-containing proteins,
including complex I (NADH-ubiquinone oxidoreductase), com-
plex II (succinate-ubiquinone oxidoreductase), and complex IV
(cytochrome C oxidase), and, therefore, blocks oxygen con-
sumption and coupled ATP production (Beltra´n et al., 2000;
Cleeter et al., 1994; Clementi et al., 1998). The general connec-
tion between reduced respiratory rate and inflammation has
been recognized for some time, and high-output NO production
by cells, such as monocyte-derived DCs and macrophages
(described below), is the underlying cause, given that NO, which
diffuses rapidly, is able to affect bystander cells within inflamed
tissue (Rees et al., 1998). At low doses in brain, liver, kidney, and
muscle cells, NO stimulates mitochondrial biogenesis, which
ultimately results in an overall increase in mitochondrial ATP
output (Nisoli et al., 2004). Whether dendritic cells are capable
of a similar response to low NO concentrations is unknown.
However, it is clear that the commitment to glycolytic meta-
bolism in activated DCs occurs only in DC subsets that express
iNOS and that it is a direct consequence of the inhibition of
OXPHOS by NO and serves as a vital survival function in order
to provide ATP in the absence of mitochondrial ATP generation
(Everts et al., 2012).
Although aerobic glycolysis is clearly important for the pro-
longed survival of activated DCs, it seems most likely that a
rapid, early increase in flux through this pathway following stim-
ulation with TLR agonists is important for initiating activation. We
base this on the fact that 2-Deoxy-D-glucose, which inhibits
glycolysis, is able to profoundly prevent early (<6 hr, which is
prior to the initiation of NO production) manifestations of activa-
tion when present at the time of DC stimulation (Krawczyk et al.,
2010). It will be important to determine whether rapid changes in
metabolism are important in other DC subsets in addition to
those derived from cultured bone marrow cells.
DCs also play an important role in maintaining tolerance. This
is exemplified by the situation in the gut, where the regulation of
potential responsiveness to the microbial flora is controlled, to a
considerable degree, by the production of retinoic acid (RA), a
small lipid metabolite of vitamin A, via gut-associated lymphoid
tissue (GALT) CD103+ DCs (Coombes et al., 2007). RA is pro-
duced from vitamin A by a process that is dependent on retinal
dehydrogenases (RALDH) and is a ligand for the nuclear recep-
tors RA receptor (RAR) and retinoid X receptor (RXR) (Nagy et al.,
2012). In the steady state, RA strongly promotes both transform-
ing growth factor b (TGF-b)-dependent inducible T regulatory
(Treg) cell development (Coombes et al., 2007; Mucida et al.,
2007; Sun et al., 2007) and the production of IgA by B cells
(Mora et al., 2006), which helps maintain intestinal barrier integ-
rity and, therefore, plays an important role in immune homeosta-
sis in this organ. These processes are consolidated by the fact
that RA induces the expression of the gut-homing molecules
a4b7 and CCR9 in a variety of immune cells, and, thereby, plays
a role in their retention within the intestine (Iwata et al., 2004).Immunity 38, April 18, 2013 ª2013 Elsevier Inc. 635
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important role in promoting the development of effector T cells
(Hall et al., 2011). This may reflect the superimposition of inflam-
mation-induced signals onto RAR and RXR signaling or function-
ally important differences in the composition of RAR and RXR
heterodimers in T cells in steady state versus inflammatory
conditions.
Macrophages
Macrophages are a key cell type in the immune system. They
exist throughout the body as resident components of most tis-
sues. These cells are embryonically derived, seeded into tissues
in utero, andmaintained by in situ proliferation (Geissmann et al.,
2010; Schulz et al., 2012). During inflammation, additional mac-
rophages of hematopoietic origin develop from monocytes re-
cruited from the bone marrow (Geissmann et al., 2010). Macro-
phages play crucial roles in innate immunity and can respond
to local immune- and/or pathogen-derived signals to adopt
different activation states. Interferon g (IFN-g), in combination
with TLR agonists, promotes M1 (or classical) activation,
whereas the cytokines IL-4 and IL-13 promoteM2 (or alternative)
activation (Benoit et al., 2008; Gordon, 2003; Murray and Wynn,
2011). From the host-defense standpoint, M1 macrophages are
inflammatory, secreting mediators such as IL-12, which pro-
motes IFN-g production by NK calls and T cells, TNF-a, which
activates other immune cells, and NO, which is directly cyto-
toxic. M1 microphages are implicated in the clearance of many
types of microbial infections. In contrast, M2 macrophages
make a range of molecules that serve to modulate inflammation,
promote tissue repair, and regulate adaptive immunity. M2 acti-
vation dominates the response to helminth parasites and is
linked to resistance to these metazoan pathogens (Anthony
et al., 2007). Intriguingly, M2 macrophages play another crucial
role linked to metabolic homeostasis, particularly within adipose
and liver tissues (Biswas and Mantovani, 2012; Odegaard and
Chawla, 2011). In lean animals, resident macrophages in these
tissues express genes associated with M2 activation. Function-
ally, M2 macrophages serve to promote insulin sensitivity by in-
hibiting M1 activation and associated inflammation. In obese
mice with insulin resistance, liver and adipose macrophages
are M1-like, and M1 products, such as TNF-a, are instrumental
in causing insulin resistance. This area is discussed in detail in
the accompanying review.
M1 and M2 activation are characterized by distinct metabolic
states that differ from those of resting macrophages (Rodrı´guez-
Prados et al., 2010). This metabolic difference is most evident in
the differential and defining difference in arginine use by these
two types of cells, M1 cells using this amino acid as a substrate
for iNOS (expressed in M1, but not M2, cells), whereas M2 mac-
rophages use arginine as a substrate for Arginase1 (which is ex-
pressed in M2, but not M1, cells) (Murray and Wynn, 2011).
Metabolically, M1 macrophages have a very glycolytic meta-
bolism and, therefore, are similar to activated bone-marrow-
derived dendritic cells (Figure 1A). Remarkably, reduced mito-
chondrial respiration serves an important role in the production
of reactive oxygen species (ROS) for host defense. Normally,
we would expect NADPH oxidase to play the dominant role in
this process, but it has been shown recently that, in macro-
phages activated by TLRs expressed at the surface membrane,636 Immunity 38, April 18, 2013 ª2013 Elsevier Inc.mitochondria are recruited to phagolysosomes in a fashion that
depends upon TNF receptor-associated factor 6 and produce
ROS that are important for killing phagocytosed bacteria (West
et al., 2011). The link between the inhibition of OXPHOS and
this process is emphasized by the fact that the treatment of mac-
rophages with the electron transport chain inhibitors rotenone
and antimycin A mimics the effects of TLR agonists in promoting
mitochondrial ROS production (West et al., 2011). Mitochondrial
stress that leads to increased ROS production also plays a key
role in the activation of the nucleotide-binding domain and
leucine-rich repeat pyrin 3 containing inflammasome. In macro-
phages infected with certain bacteria or viruses or exposed to
danger signals, such as monosodium urate or extracellular
ATP, or adjuvants, such as alum, there are coordinated in-
creases in mitochondrial ROS, IL-1b, and caspase 1 production
(Sorbara and Girardin, 2011; Tschopp and Schroder, 2010). The
key role of mitochondria in this process has been demonstrated
by the inhibition of inflammasome activation and IL-1b and cas-
pase 1 production by inhibitors of mitochondrial ROS, but not by
inhibitors of NADPH-oxidase-dependent ROS (Bulua et al.,
2011; van Bruggen et al., 2010; Zhou et al., 2011). Altogether,
these findings point to an important role for mitochondria in
inflammation and host defense, a concept further supported
by the (metabolically enigmatic) findings that mitochondria are
a platform for the induction of type 1 interferon production by ret-
inoic acid-induced gene 1 andmitochondrial antiviral signaling in
response to viral infection (Koshiba, 2013; Sun et al., 2006).
The importance of the commitment to a glucose-based meta-
bolism in activated M1 macrophages is emphasized by the fact
that the expression of carbohydrate kinase-like protein (CARKL),
which inhibits flux through the PPP, is repressed after stimulation
with TLR agonists (Haschemi et al., 2012). The PPP is essential
for M1 macrophages not only because it generates NADPH for
NADPH oxidase, which is important for ROS production, but
also because NADPH is required for NO synthesis (Aktan,
2004) and, moreover, reduces glutathione, which plays a crucial
role minimizing auto-oxidative damage by ROS.
Hypoxia inducible factor 1 (HIF-1) plays an important role in
the commitment to glycolysis by orchestrating the decision to
commit pyruvate to acetyl-CoA or to lactate (Kim et al., 2006; Pa-
pandreou et al., 2006). In order to maintain flux through the
glycolysis pathway, it is essential that NAD+ be regenerated
from NADH. This can occur in one of two ways. In normoxic con-
ditions when OXPHOS is active, the malate aspartate shuttle
provides a means for regenerating NAD+ in the cytoplasm while
at the same time producing NADH in the mitochondrial matrix to
help fuel OXPHOS. However, in conditions where OXPHOS is in-
hibited, the conversion of pyruvate into lactate becomes an
essential means of regenerating NAD+ (Locasale and Cantley,
2011) (Figure 1). HIF-1a, which is induced by hypoxia and also
by TLR agonists and proinflammatory cytokines, such as TNF-a
and IL-1b, supports this process by promoting the expression
of lactate dehydrogenase, which is responsible for the produc-
tion of lactate from pyruvate, and of pyruvate dehydrogenase
kinase, which phosphorylates and, thereby, inhibits pyruvate de-
hydrogenase—an enzyme complex that converts pyruvate into
acetyl CoA (Imtiyaz and Simon, 2010). Thus, under conditions
where OXPHOS is inhibited, HIF-1a promotes aerobic glycol-
ysis. As discussed above, increased glycolytic flux is essential
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isoforms have been shown to be crucial for activation in both cell
types (Imtiyaz et al., 2010; Jantsch et al., 2008).
In addition to changes in core ATP-generating pathways, TLR-
initiated signaling induces alterations in macrophage lipid meta-
bolism that are of interest because they are both extensive and
integral to the induction and resolution of inflammation (An-
dreyev et al., 2010a; Andreyev et al., 2010b; Anthony et al.,
2007). For example, M1 activation leads to increased meta-
bolism of arachidonic acid, the production of eicosanoids,
including the generally inflammatory leukotrienes and prosta-
noids (prostaglandins, prostacyclins, and thromboxanes)
(Greene et al., 2011). TLR agonists also lead to the increased
metabolism of eicosapentaenoic and docosahexaenoic acids
with the synthesis of nonclassic eicosanoids, such as resolvins
and lipoxins, which tend to have anti-inflammatory properties
(Serhan et al., 2011). The eicosanoids exert their diverse effects
on other cells via G protein-coupled receptors (GPCRs) that are
differentially expressed (Hirata and Narumiya, 2012; Serhan
et al., 2011). IL-4 can counter some of these effects by inhibiting,
for example, the TLR-agonist-induced expression of cyclooxy-
genase 2 (COX2), which, along with constitutively expressed
COX1, catalyzes one of the first steps in prostanoid synthesis
(Endo et al., 1998; Raetz et al., 2006). Thus, a balance of external
signals, coupled with temporal changes in the pattern of expres-
sion of different mediators from lipid substrates, will have pro-
found effects on immune cell functions and the successful initia-
tion and conclusion of inflammation. The magnitude of the
effects mediated by these pathways is attested to by the clinical
importance of drugs that target them for the treatment of, for
example, pain and asthma (reviewed in Greene et al., 2011).
Recent insights have revealed additional effects of lipid meta-
bolism on inflammation induced by TLR agonists. In M1 macro-
phages, there are increases in the concentration of the choles-
terol precursor desmosterol. Suppression of expression of
DHCR24, which catalyzes the synthesis of desmosterol, is found
to result in increased expression of inflammatory genes associ-
ated with M1 activation in mice fed a high-fat diet (Spann
et al., 2012). Desmosterol is a ligand for the nuclear receptor
LXR, and the intrinsic anti-inflammatory effects of desmosterol
have been found to be, at least in part, LXR-dependent. This is
consistent with earlier reports that LXR can inhibit TLR4-initated
macrophage activation by preventing epigenetic remodeling of
TLR4-responsive regulatory elements (Ghisletti et al., 2007;
Kidani and Bensinger, 2012).
M2 macrophages are the ying to the M1 yang. They have
higher basal mitochondrial oxygen consumption rates than
either resting macrophages or, of course, M1 macrophages.
This reflects expression of PGC-1b, an important transcrip-
tional regulator of oxidative metabolism genes, driven by signal
transducer and activator of transcription 6 (Vats et al., 2006).
Consistent with the induction of OXPHOS by IL-4, M2 macro-
phage development is profoundly prevented by the inhibition
of mitochondrial OXPHOS and, specifically, by the inhibition of
fatty acid oxidation (FAO). Thus, M2 metabolism is skewed
heavily toward the use of FAO and mitochondrial respiration to
meet functional needs (Vats et al., 2006) (Figure 1C). A funda-
mental difference between M1 and M2 macrophages is that, un-
der certain circumstances, M2macrophages are able to prolifer-ate (Jenkins et al., 2011), and, although the issue has not been
addressed experimentally, it makes sense to consider the meta-
bolic differences between the two activation states as being
instrumental in this divergence of function. As discussed in
more depth below, mitochondrial ROS are important for anti-
gen-driven T cell proliferation, and a similar relationship between
proliferative capacity and mitochondrial activity in M2 macro-
phage proliferation would be consistent with the differences in
OXPHOS between these and M1 cells. However, proliferating
macrophages must face metabolic demands specific to the re-
quirements of daughter cell production, which clearly would
require anabolic pathways. It is currently unclear how this fits
with the facts that (1) M2 macrophages primarily use catabolic
pathways such as FAO and (2) IL-4 induces the expression of
CARKL, which inhibits flux through the PPP (Haschemi et al.,
2012). This is an interesting area for future study.
There has been considerable interest in the role of peroxisome
proliferator-activated receptors (PPARs) in M2 macrophages.
PPARs are a family of nuclear receptors for fatty acid ligands.
They heterodimerize with RXR and interact with transcriptional
coactivators to control the expression of genes involved in fatty
acid metabolism (Nagy et al., 2012). Consistent with the noted
importance of FAO in M2 macrophages, PPARd, which is
responsible for promoting the expression of genes involved in
substrate oxidation and oxidative phosphorylation, has been
found to be essential for M2 differentiation (Kang et al., 2008;
Odegaard et al., 2008). Expression of this PPAR is increased in
M2 macrophages from mice exposed to parasitic helminths,
and these cells additionally contain high amounts of PGI2, an
eicosanoid ligand for PPARd (Thomas et al., 2012). Therefore,
it seems that M2 activation can be consolidated metabolically
through the production of endogenous ligands for PPARd. More-
over, PPAR response elements are abundant and overrepre-
sented in genes induced in M2 macrophages, supporting the
view that PPARs are important transcription factors that drive
this activation state (Thomas et al., 2012).
T Cells
Given the critical nature of T cells in clearing or controlling infec-
tions and cancer, as well as mediating protective immunity over
the long term, it is logical that a considerable effort is made to
target these cells for therapeutic purposes. However, although
metabolism underlies the fate and function of T cells, or of any
immune cell for that matter, metabolic interventions for manipu-
lating immunity are rare and can be considered to represent a
largely untapped opportunity. T cells differ from innate cells in
many aspects, but perhaps their ability to extensively and rapidly
proliferate upon activation is what most sets them apart from
other immune cells, at least for the purposes of this discussion.
These attributes of activated T cells have led to their ‘‘metabolic’’
comparison with tumor cells, given that both cell types have
been shown to engage Warburg metabolism when proliferating
(Fox et al., 2005; Jones and Thompson, 2007; van Bruggen
et al., 2010; Vander Heiden et al., 2009) (in contrast to most
innate cells, which engage Warburg metabolism upon activation
but do not proliferate). Another characteristic specific to cells of
the adaptive immune system is their ability to generate long-
lived, antigen-specific memory cells that mediate protection
against reinfection or tumor re-emergence. Memory T cellsImmunity 38, April 18, 2013 ª2013 Elsevier Inc. 637
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T cell counterparts, in that they do not use aerobic glycolysis
but rely on mitochondrial FAO for development and persistence
(Figure 1) (van der Windt et al., 2012).
When a naive T cell recognizes an antigen in the context of
proper costimulation, it undergoes a developmental program
characterized by rapid growth, proliferation, and acquisition
of specialized effector functions. This is an energetically
demanding process that requires metabolic reprogramming.
For cells to grow and proliferate, they must change from a cata-
bolic metabolism to an anabolic metabolism, because, unlike in
a resting cell, nutrients will no longer be utilized for maintenance
and homeostasis but, rather, will be incorporated into biomass
for new daughter cells. Similarly, T cells destined to become
memory cells must maintain or adopt a catabolic meta-
bolism—a feature that underlies their quiescence and longevity
and may even serve to impede their terminal differentiation.
There is a growing appreciation for the importance of metabolic
reprogramming in immune cells. How molecules such as
mammalian target of rapamycin, P13K, Akt, Myc, and HIF link
immune signals and metabolic cues for the activation, develop-
ment, function, and maintenance of T cells has been reviewed in
depth elsewhere (Hirata and Narumiya, 2012; Seth et al., 2006;
Waickman and Powell, 2012; Wang and Green, 2012a, b).
More specifically, metabolic pathways can influence the devel-
opment of various T helper subsets, and this has also been the
subject of several reviews (Chi, 2012; Gerriets and Rathmell,
2012; Zemirli and Arnoult, 2012). For example, Treg cells pre-
dominantly use OXPHOS and mitochondrial FAO for develop-
ment and survival (Michalek et al., 2011), whereas the generation
of T helper 17 (Th17) cells requires glycolysis (Shi et al., 2011).
Although these findings are well documented, it remains unclear
precisely why these cells must adopt these very different meta-
bolic phenotypes for their differentiation. In this discussion, we
hope to provide insight into why changes in metabolism occur
in T cells, the challenges to consider, and what remains unan-
swered in this developing field.
Although the use of heavily labeled substrates has allowed a
first look into how T cells utilize nutrients, much work still needs
to be done to understand (1) what specific nutrients are actually
providing to the cells and (2) how substrate utilization occurs
in vivo. For example, although it is known that both glucose
and glutamine are critical nutrients for T cells, precisely what
they provide to the T cell, especially in vivo during an immune
response, is not completely understood. Glucose can be
used as an example. As introduced above, the breakdown of
glucose in the glycolysis pathway generates ATP in the cyto-
plasm, but its oxidation in the mitochondria can generate
even more ATP through the production of reducing equivalents
(NADH and FADH2) to power OXPHOS. Once glucose enters
the TCA cycle (as pyruvate-derived acetyl CoA), it can also
act as a precursor for biosynthesis. For example, glucose-
derived citrate can be exported from the mitochondria to the
cytosol for the synthesis of fatty acids. In addition, glucose
can also enter the PPP at a branchpoint early in the glycolysis
pathway. The PPP is important for the production of pentose
sugars for nucleotide biosynthesis as well as for the production
of NADPH, which is a critical coenzyme for fatty acid synthesis,
and for the regeneration of reduced glutathione. For the638 Immunity 38, April 18, 2013 ª2013 Elsevier Inc.continued breakdown of glucose in the glycolysis pathway,
NAD+ is needed. Pyruvate can be excreted as lactate from
the cell as way to regenerate cytosolic NAD+, which can then
be utilized to support the glycolysis pathway. However, NAD+
can also be exported from the mitochondria via specialized
shuttles, and, in theory, the continued breakdown of glucose
could also be maintained without the excretion of lactate.
Therefore, by considering the fate of glucose in the cell, even
in this most basic way, it becomes readily apparent that pre-
cisely how this substrate is utilized is exceedingly complex.
Now, if we consider not only how, but also why, a specific sub-
strate is metabolized into a particular pathway, the picture be-
comes even more complicated. For example, glucose may be
directed to the PPP for the purpose of NADPH production or
for nucleotide synthesis. If nucleotides are not needed, then
is NADPH produced because the cell needs to elongate fatty
acids, make cholesterol, or reduce glutathione? We can further
layer these types of questions with the complexities that are
inherent in vivo during an immune response, such as differ-
ences in substrate availability in various tissues, inflammatory
signals, competition for substrates from other immune and
nonimmune cells, and how each of these alters the local bal-
ance of nutrients and growth factor signals. Thus, even though
the basic principles have been elucidated, the question of how
metabolic processes influence functional and developmental
outcomes remains far from clear. Given the fact that meta-
bolism controls the function and fate of T cells, continued
research in this area is warranted.
In addition to generating energy and reductive power and sup-
porting biosynthesis, metabolic pathways also control other key
cellular processes. In this context, recent studies have shed light
on the requirements for mitochondrial processes versus cyto-
solic metabolic pathways in fueling T cell activation, survival,
proliferation, and effector functions. An example illustrating this
idea is found in a recent study that shows a critical role for mito-
chondrial ROS in T cell activation (Sena et al., 2013). T cells from
mice with a T cell-specific reduction in a subunit of themitochon-
drial electron transport chain complex III, which leads to a reduc-
tion in ROS from this complex, is required for the activation of
NFAT and subsequent IL-2 production. Interestingly, T cells in
these mice were not able to undergo antigen-specific expansion
in response to infection, even though they were able to prolifer-
ate in a lymphopenic environment. These observations allowed
the authors conclude that cells with reduced mitochondrial
ROS are not lacking bioenergetically, as they were able to
undergo homeostatic proliferation but, rather, lack ROS-depen-
dent signaling mechanisms needed for antigen-specific T cell
activation and subsequent clonal expansion. These results high-
light how metabolic pathways can act as signaling mechanisms
to control cellular processes other than energy production or
biosynthesis directly. Emerging work from our groups also sug-
gests that a switch to, or induction of, aerobic glycolysis is not a
requirement for T cell activation and that this process actually re-
quires mitochondrial OXPHOS. The observation that prolifer-
ating cells, such as tumor cells and activated T cells (and bacte-
ria and yeast), use aerobic glycolysis has contributed to the idea
that engagement of this pathway is a prerequisite for, or occurs
hand in hand with, cellular proliferation. However, an overlooked
fact is that most cells in the innate immune system adopt
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discussed above).
Although there has been considerable interest in the meta-
bolic demands of T cell activation, less time has been spent ad-
dressing how changes in metabolism contribute to the contrac-
tion of antigen-specific cell populations after the peak of the
effector response and the generation of stable memory T cells.
Our published work has shown that memory T cells rely on mito-
chondrial FAO for their development and long-term survival
(Pearce, 2010; Pearce et al., 2009; van der Windt et al., 2012;
van der Windt and Pearce, 2012). In contrast to effector
T cells, which use glycolysis and have reduced mitochondrial
mass, memory T cells maintain greater mitochondrial mass, a
fact which supports their oxidative metabolism (van der Windt
et al., 2012). These findings led us to propose a model in which
most effector T cells die during contraction because of their bio-
energetic instability; i.e., their lack of mitochondrial maintenance
renders them unable to support OXPHOS when infection-asso-
ciated signals that maintain glycolysis decline. One picture that
seems to emerge from these findings is that substantial mito-
chondrial respiratory capacity (perhaps because of increased
mitochondrial mass, maintenance, or simply the reliance on
mitochondrial pathways) is linked to cellular longevity. Prelimi-
nary studies from our laboratory indicate that memory T cells
do have more mitochondrial mass than their naive counterparts
and that this enhanced mitochondrial mass imparts memory
T cells with a bioenergetic advantage that rapidly fuels subse-
quent reactivation. These findings would be consistent with
the idea that T cell activation requires OXPHOS. Given that
memory T cells maintain more mitochondria than naive T cells,
it will be interesting to determine where stem cell memory
T cells fall in this range (Gattinoni et al., 2011; Zhang et al.,
2005). Stem cell memory T cells are more differentiated than
naive T cells, but they are less differentiated than central or
effector memory T cells (Gattinoni et al., 2012); therefore, we
might speculate that they have substantial mitochondrial spare
respiratory capacity that supports their persistence and ability
for self-renewal. If this were the case, then increased mitochon-
drial biogenesis, which is known to occur immediately after
T cell activation (D’Souza et al., 2007), might represent one of
the first developmental steps in the generation of stem cell
memory T cells, whereas those cells that continue to rapidly
differentiate toward the effector state would not maintain mito-
chondrial numbers or capacity to the same extent or in the
same way. In this context, future investigation of mitochondrial
dynamics will be needed to determine whether terminal differen-
tiation controls or is simply marked by bioenergetic imbalance.
When considering these issues, it is worth drawing attention
to the fact that effector T cells also maintain OXPHOS in con-
junction with glycolysis, even after full activation is attained
(Sena et al., 2013; van der Windt et al., 2012; Wang et al.,
2011). However, whether this is a requirement for continued pro-
liferation or function is not clear. In addition, it is not known
whether the OXPHOS engaged in these cells is only for the
ROS signaling that is needed for proliferation (Sena et al.,
2013; Weinberg et al., 2010) or if it is also for other purposes,
such as powering ATP production directly, the regeneration of
NADH toNAD+ to support TCA cycling and production of biosyn-
thetic precursors, or to maintain mitochondrial integrity. Estab-lishing the all of the reasons why particular metabolic pathways
are used will be key to developing techniques that target meta-
bolism for immunotherapy.
B Cells
Our discussion of metabolism in the adaptive immune system
has focused on T cells. Although B cells do share certain funda-
mental metabolic characteristics with T cells, such as their
increased glucose uptake and induction of glycolysis after acti-
vation (Doughty et al., 2006; Dufort et al., 2007), much less is
known about how metabolism directs the fate of normal B cells
(a considerable amount of work has been done to investigate
metabolic pathways in cancerous B cells). Where gaps do exist
in the knowledge about B cell metabolism, one might be able to
fill in some blanks by considering parallel events in T cells. For
example, can we speculate that short-lived plasma cells and
memory B cells have similar metabolic profiles as effector
T cells and memory T cells, respectively? Given the similarity in
the functional capacity and lifespan of these cell types, this
would seem like a reasonable assumption. However, during an
immune response, B cells can also differentiate into long-lived
plasma cells, which survive within the bone marrow for years,
continuously synthesizing large amounts of antibody to maintain
physiologically relevant concentrations in plasma. Our models of
metabolism in immune cells do not easily explain how plasma
cells are able to combine longevity and high-output biosynthesis
in this way, and these cells clearly represent an important,
although challenging, subject for further work.
To What Extent Do Microenvironments Restrict Cellular
Metabolic Choices?
It has long been appreciated that, unlike bacteria or yeast, which
respond directly to nutrients in their environments, mammalian
cells must be instructed by growth factors in order to efficiently
utilize nutrients. This represents a fundamental mechanism for
the regulation of cell growth in metazoans. A classic example
of this in the immune system is how IL-2 promotes glucose trans-
porter expression and, as such, effectively directs activated
T cells toward a glycolytic metabolism (Fox et al., 2005; Rathmell
et al., 2001;Wofford et al., 2008). However, it is equally important
to consider that available nutrients, substrates, or other re-
sources may also become limited or imbalanced in immune
cell niches, affecting immune cell metabolism and, thereby,
cell function and fate. A well-characterized example of this is
tryptophan catabolism by tumors or antigen-presenting cells ex-
pressing indoleamine-2,3-dioxygenase. The utilization of this
pathway depletes tryptophan in the microenvironment, and,
with the production of immunosuppressive catabolites, nega-
tively effects T cells function and survival (Mellor and Munn,
2004; Munn and Mellor, 2013; Platten et al., 2012; Serhan
et al., 2011; Zhao et al., 2012). Competition for arginine may
also fall into this general category, given that myeloid-derived
suppressor cell populations typically express arginase and
iNOS, which, together, are capable of rapidly depleting this
amino acid from the environment (Kidani and Bensinger, 2012;
Norris et al., 2013). Given these findings, it would seem likely
that substrate availability, whether concentrations of the nutrient
itself or of the growth factors that allows its acquisition, fluctu-
ates dramatically depending on the location of the immuneImmunity 38, April 18, 2013 ª2013 Elsevier Inc. 639
Figure 2. Model for Competition for Substrates and Production of
Regulatory Metabolites at Sites of Infection or within Tumors
In the lymph nodes and blood, nutrients and other supportive signals are
abundant, and T cells are potentially able to engage Warburg metabolism and
attain full effector status. However, conflicting metabolic signals may inhibit
T cell function and fate within diseased tissues. T cells may face metabolic
restrictions, such as reduced local glucose and/or oxygen concentrations
because of rapid tumor and/or pathogen growth, and reduced vascular
perfusion. Additionally, tumors and sites of infection can be infiltrated by
suppressive myeloid cells, which aggressively deplete important substrates,
such as tryptophan and arginine, and further produce toxic gases (such as NO)
that can inhibit OXPHOS.
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damaged tissue sites, especially if perfusion is diminished (Lewis
et al., 1999).
If lymph nodes and bone marrow are considered to represent
nutrient-replete environments, would it also be reasonable to as-
sume that nutrient concentrations are precisely the same in all
other tissues, especially during infection or inflammation? For
example, as a T cell moves from the blood into the airways, as
occurs during influenza infection, does this cell experience a
nutrient restriction that influences metabolism and hampers its
ability to persist or function? Similarly, as immune cells infiltrate
a tumor or site of infection, are they effectively in competition
with tumor cells or pathogens for all key substrates? Nutrient lim-
itations leading to declines in ATP effectively trigger AMPK acti-
vation, which is amajor regulator of cellular activation because of
its ability to suppress anabolic and promote catabolic pathways.
This area has been reviewed recently (O’Neill and Hardie, 2013).
Activated AMPK promotes the oxidation of substrates in mito-
chondria and coincidentally limits the glycolytic capacity of cells.
Although this is consistent with the requirements for the develop-
ment of M2 macrophages, memory T cells, and regulatory
T cells, it is not supportive of the types of aggressive effector
functions that are usually required to deal with microbial infec-
tions or tumors. Moreover, there is evidence that inflamed
tissues are deprived of oxygen, creating an environment where
aerobic glycolysis is required for survival (Lewis et al., 1999).
Thus, the combination of the relative availability of nutrients
and oxygen within a diseased site and the ability of infiltrating im-640 Immunity 38, April 18, 2013 ª2013 Elsevier Inc.mune cells to utilize these nutrients would be expected to have a
profound effect on the outcome of the immune response.
Concluding Remarks
In this review, we discussed how metabolic pathway choices
affect immune cell function and fate. Despite considerable prog-
ress over the last 10 years, this area remains ripe for increased
investigation, especially given that virtually nothing is currently
known about the metabolism of many of the cell types in the im-
mune system. Research on metabolism has been difficult for a
nonexpert to access, in part because many of the experimental
approaches require specialized instrumentation. Moreover,
metabolomics, the identification of relative amounts of ‘‘all
metabolites’’ is technically challenging and, therefore, not widely
available. Thus, access to hypothesis-generating, unbiased
global metabolite data sets analogous to the gene expression
profiling that can be generated through microarrays or RNA
sequencing is limited. Nevertheless, this situation is changing
(e.g., Karnovsky et al., 2012), and we can expect considerable
steps forward in our understanding of metabolism in immunity
in the near future.
Other exciting prospects for the future include increased un-
derstanding of how metabolites initiate signaling pathways to
induce changes in cellular function. For example, it is now clear
that there is a large number of GPCRs, previously categorized as
orphan receptors, that are, in fact, receptors for metabolic inter-
mediates and energy substrates (Blad et al., 2012). There is
growing evidence that these types of receptors play important
roles in immune cells. For example, succinate working through
the succinate receptor GPR91 is able to directly promote
chemotaxis and potentiate activation initiated by TLR agonists
in DCs (Rubic et al., 2008). Moreover, adenosine, through the
A2B and A2A adenosine receptors, strongly promotes IL-4
driven M2 activation in macrophages (Cso´ka et al., 2012).
When considering how cells respond to metabolites, it seems
reasonable to consider whether pathogens or tumor cells pro-
duce unusual metabolites that affect immune cell function. In
this regard, it is interesting that gdT cells expressing Vg9 and
Vd2 receptors are specifically responsive to themicrobial metab-
olite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (Eberl
and Moser, 2009). It seems likely that we are aware of just the
tip of the iceberg when it comes to these types of interactions,
and it will be exciting to see progress in this area in the future.
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